Statin prescribing in Europe: A comparison of differences and potential impact on health outcomes

Primary Care Cardiovascular Journal

Volumn 5, Issue 3, 2012, Pages 127-131

  Liew, Danny ^a   Webb, Kate ^a   Van Vugt, Joris ^b   Bonnet, Jacques ^c   Clemmensen, Peter ^d   Phillips, Ceri ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG MECHANISM; EUROPE; HUMAN; MYOPATHY; PRESCRIPTION; REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

EID: 84867509266     PISSN: 17565138     EISSN: 17565146     Source Type: Journal    
DOI: 10.3132/pccj.2012.052     Document Type: Review

References (23)

1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
3. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76.
4. Rogers SL, Magliano DJ, Levison DB et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007; 29:242-52. (Pubitemid 46654221)
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
6. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
7. Agence Française de Sécurité Sanitaire des Produits de Santé. Recommandations de l'Afssaps (Mars 2005). Prise en charge thérapeutique du patient dyslipidémique. [AFSSAPS guideline for the treatment of dyslipidemia]. Rev Prat 2005;55:1788-93.
8. IMS Health. IMS MIDAS, June 2011, volume (counting units).
9. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
10. Delahoy PJ, Magliano DJ, Webb K et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009;31:236-44.
11. Blak BT, Gabriel ZL, Hards M, Minhas I. Variations in lipid levels across the UK - a THIN database study. Paper presented at: Primary Care Cardiovascular Society 13th Annual Scientific Meeting; September, 2010; Leeds, UK.
12. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82.
13. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
14. Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16:121-37. doi: 10.1097/HJR.0b013e3283294b1d.
15. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16. doi: 10.1001/jama.292.11. 1307. (Pubitemid 39223221)
16. Armitage J, Bowman L, Wallendszus K et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a doubleblind randomised trial. Lancet 2010;376:1658-69. doi: 10.1016/S0140-6736(10)60310-8.
17. U.S. Food and Drug Administration. FDA: Limit use of 80 mg simvastatin. Last update: 8 June 2011. Available from: www.fda.gov/ForConsumers/ ConsumerUpdates/ucm257884.htm. Accessed 16 April, 2012.
18. Krasuski RA, Doeppenschmidt D, Henry JS et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. Mayo Clin Proc 2005; 80:1163-8. (Pubitemid 41233353)
19. Waters DD, Brotons C, Chiang CW et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34.
20. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal 94, 2008. Available from: www.nice.org.uk/nicemedia/live/11564/33151/33151.pdf.
21. Piette JD, Heisler M. Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care 2004;10:861-8.
22. Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy 2005;4:23-35. (Pubitemid 41352123)
23. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med 2007;4:e283.